Compare Stocks: ORGO, DBVT, FDMT, and SLN

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DBVT DBV Technologies	$12.35 -1.3%	$13.86	$8.85 ▼ $26.18	$776.54M	-0.95	279,196 shs	137,641 shs
FDMT 4D Molecular Therapeutics	$15.22 +3.7%	$12.79	$6.47 ▼ $16.93	$840.81M	2.74	778,316 shs	1.79 million shs
ORGO Organogenesis	$1.42 +4.4%	$1.98	$1.34 ▼ $7.08	$182.72M	1.29	647,896 shs	1.00 million shs
SLN Silence Therapeutics	$12.20 -3.9%	$12.63	$4.19 ▼ $17.58	$734.55M	1.45	709,238 shs	1.14 million shs

Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DBVT DBV Technologies	0.00%	+4.22%	-13.27%	-20.48%	+26.73%
FDMT 4D Molecular Therapeutics	0.00%	+15.57%	-5.47%	+57.56%	+128.53%
ORGO Organogenesis	0.00%	-4.70%	-22.83%	-41.80%	-69.26%
SLN Silence Therapeutics	0.00%	-6.30%	-7.37%	+76.05%	+143.51%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DBVT DBV Technologies	$12.35 -1.3%	$13.86	$8.85 ▼ $26.18	$776.54M	-0.95	279,196 shs	137,641 shs
FDMT 4D Molecular Therapeutics	$15.22 +3.7%	$12.79	$6.47 ▼ $16.93	$840.81M	2.74	778,316 shs	1.79 million shs
ORGO Organogenesis	$1.42 +4.4%	$1.98	$1.34 ▼ $7.08	$182.72M	1.29	647,896 shs	1.00 million shs
SLN Silence Therapeutics	$12.20 -3.9%	$12.63	$4.19 ▼ $17.58	$734.55M	1.45	709,238 shs	1.14 million shs

Don't Wait for the OpenAI IPO

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DBVT DBV Technologies	0.00%	+4.22%	-13.27%	-20.48%	+26.73%
FDMT 4D Molecular Therapeutics	0.00%	+15.57%	-5.47%	+57.56%	+128.53%
ORGO Organogenesis	0.00%	-4.70%	-22.83%	-41.80%	-69.26%
SLN Silence Therapeutics	0.00%	-6.30%	-7.37%	+76.05%	+143.51%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
DBVT DBV Technologies	2.57	Moderate Buy	$48.50	292.71% Upside
FDMT 4D Molecular Therapeutics	2.82	Moderate Buy	$28.56	87.62% Upside
ORGO Organogenesis	1.67	Reduce	$4.33	205.16% Upside
SLN Silence Therapeutics	2.83	Moderate Buy	$53.50	338.52% Upside

Current Analyst Ratings Breakdown

Latest ORGO, DBVT, FDMT, and SLN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/14/2026	FDMT 4D Molecular Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Neutral ➝ Overweight	$20.00
9/10/2026	DBVT DBV Technologies	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight
9/4/2026	ORGO Organogenesis	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/21/2026	ORGO Organogenesis	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D) ➝ Sell (D-)
8/17/2026	FDMT 4D Molecular Therapeutics	B. Riley Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/13/2026	FDMT 4D Molecular Therapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$32.00
8/11/2026	SLN Silence Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$25.00 ➝ $32.00
8/7/2026	ORGO Organogenesis	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D)
8/7/2026	ORGO Organogenesis	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Hold	$3.00 ➝ $2.00
7/31/2026	FDMT 4D Molecular Therapeutics	B. Riley Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$37.00
7/28/2026	FDMT 4D Molecular Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy

(Data available from 9/20/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
DBVT DBV Technologies	N/A	N/A	N/A	N/A	$4.20 per share	N/A
FDMT 4D Molecular Therapeutics	$85.21M	9.87	N/A	N/A	$8.85 per share	1.72
ORGO Organogenesis	$564.17M	0.32	$0.65 per share	2.19	$2.36 per share	0.60
SLN Silence Therapeutics	$560K	1,311.72	N/A	N/A	$1.32 per share	9.24

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
DBVT DBV Technologies	-$146.95M	-$3.51	N/A	N/A	N/A	-3,506.53%	-119.33%	-84.43%	10/28/2026 (Estimated)
FDMT 4D Molecular Therapeutics	-$140.11M	-$2.63	N/A	N/A	N/A	-194.74%	-41.33%	-35.90%	11/10/2026 (Estimated)
ORGO Organogenesis	$37.03M	-$0.86	N/A	N/A	N/A	-19.94%	-23.89%	-11.13%	11/5/2026 (Estimated)
SLN Silence Therapeutics	-$88.61M	-$1.28	N/A	N/A	N/A	-8,943.86%	-106.94%	-47.99%	11/5/2026 (Estimated)

Latest ORGO, DBVT, FDMT, and SLN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	FDMT 4D Molecular Therapeutics	-$1.02	-$1.04	-$0.02	-$1.04	$3.62 million	$3.78 million
8/10/2026	Q2 2026	SLN Silence Therapeutics	-$0.1387	-$0.26	-$0.1213	-$0.27	$1.13 million	N/A
8/6/2026	Q2 2026	ORGO Organogenesis	-$0.35	-$0.71	-$0.36	-$0.77	$54.27 million	$43.76 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
DBVT DBV Technologies	N/A	N/A	N/A	N/A	N/A
FDMT 4D Molecular Therapeutics	N/A	N/A	N/A	N/A	N/A
ORGO Organogenesis	N/A	N/A	N/A	N/A	N/A
SLN Silence Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
DBVT DBV Technologies	N/A	3.72	3.72
FDMT 4D Molecular Therapeutics	0.05	8.03	8.03
ORGO Organogenesis	0.07	3.52	3.00
SLN Silence Therapeutics	N/A	7.42	7.42

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
DBVT DBV Technologies	71.74%
FDMT 4D Molecular Therapeutics	99.27%
ORGO Organogenesis	49.57%
SLN Silence Therapeutics	98.73%

Insider Ownership

Company	Insider Ownership
DBVT DBV Technologies	1.06%
FDMT 4D Molecular Therapeutics	7.90%
ORGO Organogenesis	18.80%
SLN Silence Therapeutics	3.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
DBVT DBV Technologies	161	62.88 million	62.21 million	Optionable
FDMT 4D Molecular Therapeutics	196	55.24 million	50.88 million	Optionable
ORGO Organogenesis	854	128.68 million	104.48 million	Optionable
SLN Silence Therapeutics	88	60.21 million	58.40 million	Not Optionable

ORGO, DBVT, FDMT, and SLN Headlines

Recent News About These Companies

Silence Therapeutics plc (SLN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

September 16, 2026 | seekingalpha.com

Silence Therapeutics (NASDAQ:SLN) Stock Price Down 5.4% - Here's Why

September 15, 2026 | marketbeat.com

Seven Fleet Capital Management LP Sells 96,652 Shares of Silence Therapeutics PLC Sponsored ADR $SLN

September 5, 2026 | marketbeat.com

Silence Therapeutics to Participate in Three September Investor Conferences

September 2, 2026 | cityam.com

Silence Therapeutics (NASDAQ:SLN) Stock Price Up 5.8% - Should You Buy?

September 1, 2026 | marketbeat.com

Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN) Given Consensus Recommendation of "Moderate Buy" by Analysts

August 31, 2026 | marketbeat.com

5AM Venture Management LLC Makes New Investment in Silence Therapeutics PLC Sponsored ADR $SLN

August 26, 2026 | marketbeat.com

Silence Therapeutics: Making Some Recent Noise

August 19, 2026 | seekingalpha.com

Silence Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional ADSs

August 14, 2026 | businesswire.com

Silence Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional ADSs

August 14, 2026 | cityam.com

Wall Street Analysts Predict a 140.06% Upside in Silence Therapeutics (SLN): Here's What You Should Know

August 13, 2026 | zacks.com

Analysts Are Bullish on Top Healthcare Stocks: MoonLake Immunotherapeutics (MLTX), Silence Therapeutics (SLN)

August 12, 2026 | theglobeandmail.com

Silence Therapeutics (SLN) Receives a Buy from Morgan Stanley

August 12, 2026 | theglobeandmail.com

Analysts Conflicted on These Healthcare Names: Silence Therapeutics (SLN), Hims & Hers Health (HIMS) and Syndax Pharmaceuticals (SNDX)

August 12, 2026 | theglobeandmail.com

Silence Therapeutics Announces Pricing of Upsized $175 Million Underwritten Public Offering

August 11, 2026 | businesswire.com

Morgan Stanley maintains Overweight rating on Silence Therapeutics

August 11, 2026 | seekingalpha.com

Silence Therapeutics plc (SLN) Discusses Top-Line Results From SANRECO Phase II Trial of Divesiran in Polycythemia Vera - Slideshow

August 11, 2026 | seekingalpha.com

Silence Therapeutics plc (SLN) Discusses Top-Line Results From SANRECO Phase II Trial of Divesiran in Polycythemia Vera Transcript

August 10, 2026 | seekingalpha.com

Silence Therapeutics' Divesiran to Treat Polychthemia Vera Meets Primary, Secondary Endpoints

August 10, 2026 | finance.yahoo.com

Silence Therapeutics stock surges as divesiran trial results fuel optimism

August 10, 2026 | seekingalpha.com

Silence Therapeutics says blood cancer trial delivers 'best-case outcome'

August 10, 2026 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ORGO, DBVT, FDMT, and SLN Company Descriptions

DBV Technologies NASDAQ:DBVT

$12.35 -0.16 (-1.28%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$12.35 0.00 (0.00%)

As of 09/18/2026 04:10 PM Eastern

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. The company's earlier stage research programs includes vaccine for the respiratory syncytial virus, potential treatments for inflammatory bowel disease, celiac disease, and type I diabetes. In addition, it develops Viaskin technology platform, a platform to potentially treat food allergy. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.

4D Molecular Therapeutics NASDAQ:FDMT

$15.22 +0.54 (+3.68%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$15.08 -0.14 (-0.89%)

As of 09/18/2026 07:30 PM Eastern

4D Molecular Therapeutics, Inc., a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology. Its product pipeline includes 4D-150, which is in phase 1/2 clinical trial for the treatment of wet age-related macular degeneration; and is in phase 1/2 clinical trial for the treatment of diabetic macular edema. The company develops 4D-125, which is in phase 1/2 clinical trial for the treatment of x-linked retinitis pigmentosa; 4D-110, which is in phase 1/2 clinical trial for the treatment of choroideremia; 4D-710, which is in phase 1/2 clinical trial for the treatment cystic fibrosis lung disease; and 4D-310 to treat fabry disease cardiomyopathy and is in phase 1/2 clinical trial. In addition, its product candidates comprises 4D-175, which is in pre-clinical development for the treatment for geographic trophy; and 4D-725 to treat alpha-1 antitrypsin deficiency lung disease and is in pre-clinical development. The company has collaboration and licensing agreements with Arbor Biotechnologies, Inc.; Astellas Gene Therapies, Inc; uniQure biopharma B.V.; and Cystic Fibrosis Foundation. 4D Molecular Therapeutics, Inc. was founded in 2013 and is headquartered in Emeryville, California.

Organogenesis NASDAQ:ORGO

$1.42 +0.06 (+4.41%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$1.44 +0.02 (+1.06%)

As of 09/18/2026 07:36 PM Eastern

Organogenesis Holdings Inc., a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage. Its products also include FortiShield, a biosynthetic wound matrix for use as a temporary protective covering; PuraPly MZ, a micronized particulate version of PuraPly for the management of open wounds in the surgical setting; and CYGNUS Dual, a dehydrated placental tissue preserved to retain the ECM scaffold. The company's pipeline products include ReNu, a cryopreserved suspension used to support healing of soft tissues; PuraForce, a bioengineered porcine collagen surgical matrix for use in soft tissue reinforcement applications; and TransCyte, a bioengineered tissue for the treatment of partial thickness burns. It serves hospitals, wound care centers, government facilities, ambulatory service centers, and physician office through direct sales representives and independent agencies. Organogenesis Holdings Inc. was founded in 1985 and is headquartered in Canton, Massachusetts.

Silence Therapeutics NASDAQ:SLN

$12.20 -0.50 (-3.94%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$12.14 -0.06 (-0.49%)

As of 09/18/2026 07:30 PM Eastern

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver. The company develops Zerlasiran (SLN360), which is in phase 2 clinical trial for cardiovascular disease associated with elevated lipoprotein(a); and Divesiran (SLN124), an siRNA molecule that is in Phase I clinical trials for the treatment of genetic hematological conditions, including polycythemia vera. It is also developing SLN-COMP-1 and SLN-COMP-2 for complement-mediated diseases; and SLN-HAN-1 and SLN-HAN-2. It has collaboration agreements with AstraZeneca PLC to discover, develop, and commercialize siRNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; Hansoh Pharmaceutical Group Company Limited to develop siRNAs; and Mallinckrodt Pharma IP Trading DAC to develop and commercialize RNAi drug targets designed to silence the complement cascade in complement-mediated disorders. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc was incorporated in 1994 and is headquartered in London, the United Kingdom.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ORGO, DBVT, FDMT, and SLN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ORGO, DBVT, FDMT, and SLN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ORGO, DBVT, FDMT, and SLN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ORGO, DBVT, FDMT, and SLN Company Descriptions

DBV Technologies NASDAQ:DBVT

4D Molecular Therapeutics NASDAQ:FDMT

Organogenesis NASDAQ:ORGO

Silence Therapeutics NASDAQ:SLN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ORGO, DBVT, FDMT, and SLN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ORGO, DBVT, FDMT, and SLN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ORGO, DBVT, FDMT, and SLN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ORGO, DBVT, FDMT, and SLN Company Descriptions

DBV Technologies NASDAQ:DBVT

4D Molecular Therapeutics NASDAQ:FDMT

Organogenesis NASDAQ:ORGO

Silence Therapeutics NASDAQ:SLN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools